title: Invasive pneumococcal disease in Australia, 2011 and 2012.
abstract: In Australia, there were 1,883 cases (8.3 per 100,000 population) of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System (NNDSS) in 2011 and 1,823 cases (8.0 per 100,000) in 2012. The overall rate of IPD in Indigenous Australians was 9 times the rate of IPD in non-Indigenous Australians in 2011 and 7 times in 2012. Following the July 2011 introduction of the 13-valent pneumococcal conjugate vaccine (13vPCV) to the National Immunisation Program, rates of IPD in children aged less than 5 years decreased from 19.5 per 100,000 in 2011 to 12.6 per 100,000 in 2012. In Indigenous adults aged 50 years or over the rates of IPD caused by serotypes included in the 23-valent pneumococcal polysaccharide vaccine (23vPPV) continued to increase in both 2011 (47.2 per 100,000) and 2012 (51.2 per 100,000). The rates of IPD in non-Indigenous adults aged 65 years or over caused by serotypes included in the 23vPPV also increased in 2011 (10.1 per 100,000) and 2012 (11.2 per 100,000). There were 134 deaths attributable to IPD in 2011 and 126 in 2012, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remained low and reduced susceptibility to ceftriaxone/cefotaxime continued to be rare.
authors: Vaccine Preventable Diseases Surveillance Section, Office of Health Protection, Australian Government Department of Health, Canberra, Australian Capital Territory.
authors: Cindy
authors: C
authors: Toms
authors: Vaccine Preventable Diseases Surveillance Section, Office of Health Protection, Australian Government Department of Health, Canberra, Australian Capital Territory.
authors: Rachel
authors: R
authors: de Kluyver
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D018563:Disease Notification; D024881:Drug Resistance, Bacterial; D005260:Female; D005843:Geography; D049674:History, 21st Century; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009026:Mortality; D017063:Outcome Assessment, Health Care; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000266:history / Q000382:microbiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000145:classification / Q000276:immunology; D011159:Population Surveillance; D012307:Risk Factors; D065288:Serogroup; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects; D014611:Vaccination; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines